Skip to main content

Advertisement

SpringerLink
Log in

The Evolving Role of Cytotoxic Chemotherapy in the Management of Patients with Metastatic Prostate Cancer

  • Genitourinary Cancers (W Oh and M Galsky, Section Editors)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion Statement

Prostate cancer (PC) is the most common cancer in men in the United States. Although outcomes are excellent for early-stage disease, survival for men with metastatic PC is limited. While older studies did not supported the use of chemotherapy in PC, the efficacy of taxane chemotherapy plus prednisone is now well established in men with metastatic castration resistant PC (CRPC). The results of CHAARTED trial have further expanded the use of chemotherapy to patients with metastatic hormone-sensitive disease. The clinical efficacy of taxanes over other chemotherapeutics may be a result of its ability to inhibit microtubule-dependent trafficking of proteins such as the androgen-receptor (AR). Ongoing research uses chemotherapy earlier in the disease course as well as explores the utility of combining cytotoxic chemotherapy with biologic agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as • Of importance •• Of major importance

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

    Article  PubMed  Google Scholar 

  2. Walz J, Joniau S, Chun FK, et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int. 2011;107:765–70.

    Article  PubMed  Google Scholar 

  3. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368:1314–25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance). J Clin Oncol. 2014;32:1143–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149–58. This is a randomized, phase III trial of early docetaxel for men with metastatic prostate cancer, with a nonstatistically significant trend for survival benefit; the trial enrolled men with mostly low volume metastatic disease.

    Article  CAS  PubMed  Google Scholar 

  6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. This landmark randomized trial shows a survival benefit to docetaxel/prednisone given every 3 weeks in the first-line treatment of mCRPC.

    Article  CAS  PubMed  Google Scholar 

  7. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–64. This is the first randomized, phase III, clinical trial to show that mitoxantrone benefits men with mCRPC. The authors demonstrated an improvement in overall pain scores, which was their primary endpoint. No OS benefit was observed with this agent.

    CAS  PubMed  Google Scholar 

  8. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54. This landmark, phase III, clinical trial showing that treatment with cabazitaxel/prednisone improves OS when used in men with mCRPC who have progressed on docetaxel/prednisone.

    Article  PubMed  Google Scholar 

  9. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Beer T, Armstrong AJ, Sternberg CN, Higano CS. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study.J Clin Oncol 32, 2014 (suppl 4; abstr LBA1).

  11. De Wit R, Fizazi K, Jinga V, Edstathiou E. Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). J Clin Oncol. 2014;32:5s. suppl; abstr 5008.

  12. Eisenberger MA, Simon R, O'Dwyer PJ, et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985;3:827–41.

    CAS  PubMed  Google Scholar 

  13. Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol. 1985;3:1013–21.

    CAS  PubMed  Google Scholar 

  14. Berry W, Dakhil S, Modiano M, et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002;168:2439–43.

    Article  CAS  PubMed  Google Scholar 

  15. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506–13. This is a phase III randomized trial that confirmed the palliative benefit of mitoxantrone.

    CAS  PubMed  Google Scholar 

  16. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20. This randomized, phase III, clinical trial shows an OS benefit to giving docetaxel-based chemotherapy in combination with estramustine compared with mitoxantrone/prednisone in men with mCRPC.

    Article  CAS  PubMed  Google Scholar 

  17. Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011;7:497–506.

    Article  CAS  PubMed  Google Scholar 

  18. Sweeney C, Chen Y-H, Carducci M, Lui G. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol. 2014;32:5s. This landmark, phase III, randomized, controlled trial shows an OS benefit to adding docetaxel prednisone to ADT in men with metastatic, hormone-sensitive PC.

    Article  Google Scholar 

  19. Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol. 2001;28:8–15.

    Article  CAS  PubMed  Google Scholar 

  20. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol. 2001;12:1273–9.

    Article  CAS  PubMed  Google Scholar 

  21. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014;12:686–718.

    CAS  PubMed  Google Scholar 

  22. Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14:117–24. A phase III trial demonstrating improved safety and efficacy for every 2-week docetaxel and prednisone.

    Article  CAS  PubMed  Google Scholar 

  23. Aller A, Kraus L, M-C B. In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines. Proc Am Assoc Cancer Res. 2000;41:303. abstr 1923.

  24. Jevtana. JEVTANA® Prescribing Information. Bridgewater, NJ: sanofi-aventis U.S. LLC; March 2014.

  25. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–205.

    Article  CAS  PubMed  Google Scholar 

  26. Gao W, Bohl CE, Dalton JT. Chemistry and structural biology of androgen receptor. Chem Rev. 2005;105:3352–70.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Brown CJ, Goss SJ, Lubahn DB, et al. Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am J Hum Genet. 1989;44:264–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  28. Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71:6019–29.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res. 2011;17:3876–83.

    Article  CAS  PubMed  Google Scholar 

  30. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447–54.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Mitsiades N, Sung CC, Schultz N, et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 2012;72:6142–52.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Bryce A, Ryan CJ. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. Clin Pharmacol Ther. 2012;91:101–8.

    Article  CAS  PubMed  Google Scholar 

  33. Attard G, Richards J, de Bono JS. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res. 2011;17:1649–57.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Thadani-Mulero M, Nanus DM, Giannakakou P. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res. 2012;72:4611–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68:5469–77.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–9.

    Article  PubMed  Google Scholar 

  37. Nadiminty N, Gao AC. Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol. 2012;30:287–95.

    Article  CAS  PubMed  Google Scholar 

  38. Hörnberg E, Ylitalo EB, Crnalic S, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One. 2011;6:e19059.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Thadani-Mulero M, Portella L, Sun S, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 2014;74:2270–82.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Liu G, Chen YH, Dipaola R, et al. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin Cancer. 2012;10:99–105.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Harzstark AL, Rosenberg JE, Weinberg VK, et al. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. Cancer. 2011;117:2419–25.

    Article  CAS  PubMed  Google Scholar 

  42. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005;23:1439–46.

    Article  CAS  PubMed  Google Scholar 

  43. Ross RW, Beer TM, Jacobus S, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008;112:521–6.

    Article  CAS  PubMed  Google Scholar 

  44. Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003;98:2592–8.

    Article  CAS  PubMed  Google Scholar 

  45. Lee JL, Ahn JH, Choi MK, et al. Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed. Br J Cancer. 2014;110:2472–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Wosikowski K, Lamphere L, Unteregger G, et al. Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol. 2007;60:589–600.

    Article  CAS  PubMed  Google Scholar 

  47. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27:5431–8. A randomized phase III trial demonstrating superiority of satraplatin over placebo based upon the study definition in a population where half received previous docetaxel.

    Article  CAS  PubMed  Google Scholar 

  48. Têtu B, Ro JY, Ayala AG, et al. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer. 1987;59:1803–9.

    Article  PubMed  Google Scholar 

  49. Ro JY, Têtu B, Ayala AG, Ordóñez NG. Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases. Cancer. 1987;59:977–82.

    Article  CAS  PubMed  Google Scholar 

  50. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol. 1992;147:804–7.

    CAS  PubMed  Google Scholar 

  51. Beltran H, Tomlins S, Aparicio A, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res. 2014;20:2846–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Beltran H, Tagawa ST, Park K, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol. 2012;30:e386–9.

    Article  PubMed  Google Scholar 

  53. Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487–95.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Tagawa S, Akhtar N, Robinson B. Uncommon cancers of the prostate. In: Raghavan D, editor. Textbook of Uncommon Cancer. 4th ed. Hoboken: Wiley; 2012.

    Google Scholar 

  55. Amato RJ, Logothetis CJ, Hallinan R, et al. Chemotherapy for small cell carcinoma of prostatic origin. J Urol. 1992;147:935–7.

    CAS  PubMed  Google Scholar 

  56. Culine S, El Demery M, Lamy PJ, et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol. 2007;178:844–8. discussion 848.

  57. Galanis E, Frytak S, Lloyd RV. Extrapulmonary small cell carcinoma. Cancer. 1997;79:1729–36.

    Article  CAS  PubMed  Google Scholar 

  58. Papandreou CN, Daliani DD, Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002;20:3072–80.

    Article  CAS  PubMed  Google Scholar 

  59. Fléchon A, Pouessel D, Ferlay C, et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol. 2011;22:2476–81.

    Article  PubMed  Google Scholar 

  60. Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19:3621–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Beltran H, Rubin M, Mosquera J, Christos P. A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer. J Clin Oncol 31, 2013 (suppl; abstr TPS5096).

  62. Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38:756–67.

    Article  PubMed Central  PubMed  Google Scholar 

  63. Mosquera JM, Beltran H, Park K, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia. 2013;15:1–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  64. Beltran H, Yelensky R, Frampton GM, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol. 2013;63:920–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Nanus D, Loftus M, Hassan Akhtar N, Tagawa S. Prospective analysis of prostate cancer (PC) circulating tumor cells (CTCs) to predict response to docetaxel (DOC) chemotherapy. J Clin Oncol 30, 2012 (suppl 5; abstr 100)

  66. Thalgott M, Horn T, Heck MM, et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. J Hematol Oncol. 2014;7:20.

    Article  PubMed Central  PubMed  Google Scholar 

  67. Chi KN, Chin JL, Winquist E, et al. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol. 2008;180:565–70. discussion 570.

  68. Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004;63:1138–42.

    Article  PubMed  Google Scholar 

  69. Fizazi K, Laplanche A, Lesaunier F, Delva R. Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial. J Clin Oncol. 2014;32:5s. suppl; abstr 5005.

  70. Guttilla A, Bortolus R, Giannarini G, et al. Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial. Radiat Oncol. 2014;9:24.

    Article  PubMed Central  PubMed  Google Scholar 

  71. Patel AR, Sandler HM, Pienta KJ. Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. Clin Genitourin Cancer. 2005;4:212–4.

    Article  PubMed  Google Scholar 

  72. Rosenthal SA, Bae K, Pienta KJ, et al. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys. 2009;73:672–8.

    Article  CAS  PubMed  Google Scholar 

  73. Dorff TB, Flaig TW, Tangen CM, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011;29:2040–5.

    Article  PubMed Central  PubMed  Google Scholar 

  74. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74.

    Article  PubMed  Google Scholar 

  75. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540–5.

    Article  CAS  PubMed  Google Scholar 

  76. Friedland DM, Feinstein TM, Braffet MJ, Nelson JB. Cytotoxic chemotherapy with androgen deprivation for biochemically recurrent prostate cancer following radical prostatectomy: A retrospective review. J Clin Oncol. 2008;26(15S):16092. May 20 Supplement.

  77. Nakabayashi M, Xie W, Buckle G, et al. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology. 2013;81:611–6.

    Article  PubMed  Google Scholar 

  78. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30:1534–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  79. Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011;29(16):2191–8.

    Article  CAS  PubMed  Google Scholar 

  80. Quinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013;14:893–900.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  81. Fizazi KS, Higano CS, Nelson JB, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2013;31:1740–7.

    Article  CAS  PubMed  Google Scholar 

  82. Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013;14:760–8.

    Article  CAS  PubMed  Google Scholar 

  83. Araujo JC, Trudel GC, Saad F, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013;14:1307–16.

    Article  CAS  PubMed  Google Scholar 

  84. Petrylak D, Fizazi K, Sternberg C. A Phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer (CRPC): The MAINSAIL trial. 2012 ESMO Congress. Abstract LBA24. Presented September 30, 2012.

  85. Chi KN, De Bono JS, Higano CS. SYNERGY: A randomized phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol 29: 2011 (suppl; abstr TPS180).

  86. Small E, Demkow T, Gerritsen WR. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Abstract Number:07.

  87. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

    Article  PubMed Central  PubMed  Google Scholar 

  88. Tagawa S, Nanus D, Posadas E et al. Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 32, 2014 (suppl 4; abstr 205).

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Elan Diamond, María del Carmen Garcias, and Beerinder Karir declare that they have no conflict of interest.

Scott T. Tagawa received grants and personal fees from Sanofi-Aventis, Medivation/Astellas, Janssen, and Dendreon.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, 525 East 68th Street, New York, NY, 10065, USA

    Elan Diamond M.D., Beerinder Karir M.D. & Scott T. Tagawa M.D.

  2. Division of Medical Oncology, Department of Medicine, Hospital Son Espases, Palma de Mallorca, Spain

    María del Carmen Garcias M.D.

Authors
  1. Elan Diamond M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. María del Carmen Garcias M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beerinder Karir M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Scott T. Tagawa M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scott T. Tagawa M.D..

Additional information

This article is part of the Topical Collection on Genitourinary Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Diamond, E., del Carmen Garcias, M., Karir, B. et al. The Evolving Role of Cytotoxic Chemotherapy in the Management of Patients with Metastatic Prostate Cancer. Curr. Treat. Options in Oncol. 16, 9 (2015). https://doi.org/10.1007/s11864-014-0324-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-014-0324-2

Keywords

Search

Navigation